Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from China’s National Medical Products Administration (NMPA) for its peptide drug HRS-4729. This development marks a significant step forward in the company’s pipeline of innovative drugs.
HRS-4729: A Triple Agonist for Diabetes Treatment
HRS-4729 is a triple agonist at the glucagon-like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This unique profile distinguishes HRS-4729 from dual GLP-1/GIP receptor agonists by increasing GCG target activation, promoting energy expenditure, lowering blood lipids, and exerting weight loss effects through the regulation of glucose and lipid metabolism and suppression of appetite. The drug’s potential to offer a more comprehensive approach to diabetes management is significant, as no similar product is approved worldwide.
Global Partnership and Licensing Deal
HRS-4729 was part of the GLP-1 portfolio products licensed to Hercules Pharmaceuticals, Inc. in May this year. The US firm agreed to pay Hengrui up to USD 6 billion alongside a 19.9% equity stake, highlighting the global interest and potential value of HRS-4729 in the diabetes treatment market.-Fineline Info & Tech
